Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

The relationship between striatal glutamatergic markers and measures of striatal volume in antipsychotic-naïve patients with first-episode psychosis and medicated patients with chronic schizophrenia: a study with implications for glutamate-mediated excitotoxicity

EF 2015-16

Résumé
Schizophrenia is a psychiatric illness that affects 1% of the population. It is among the top ten causes of disability worldwide and results in enormous economic costs to the Canadian health care system. Various abnormalities in brain structure are frequently observed in patients with schizophrenia, the most common of which are reductions in volume. Importantly, volume deficits are commonly associated with increased symptoms and functional decline, although the mechanism by which they occur is currently unexplained. Glutamate is a brain chemical that can be toxic when present at abnormally high concentrations. Previous literature suggests increased glutamate levels in early and untreated schizophrenia, although levels normalize following effective treatment. Elevated levels of glutamate might cause the aforementioned brain volume losses. Our study aims to explore if glutamate levels are linked with brain loss in a region referred to as the striatum, which is highly involved in schizophrenia. We will investigate this relationship in a never-treated sample of patients who are early in their illness and in treated patients who have had schizophrenia for a significant duration of time. We hypothesize that the former group will have high glutamate levels associated with local volume losses, while no such relationship will exist in the latter group. Glutamate levels and brain volume will be measured using non-invasive magnetic resonance imaging techniques, which have been previously used to show anomalies in both glutamate and brain volume in patients with schizophrenia. Our results will be highly impactful for schizophrenia researchers by leading to an improved understanding of the illness. Additionally, this study will benefit the Canadian health care system, as well as Canadian patients and families affected by schizophrenia, by contributing to the development of new diagnostic and therapeutic strategies, ultimately improving the management and outcomes of the illness.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
339609
Name
Plitman Eric
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
The relationship between striatal glutamatergic markers and measures of striatal volume in antipsychotic-naïve patients with first-episode psychosis and medicated patients with chronic schizophrenia: a study with implications for glutamate-mediated excitotoxicity
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Antipsychotics; Brain Imaging; Excitotoxicity; First-Episode Psychosis; Glutamate; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Psychosis; Schizophrenia; Volume
Abstract
Schizophrenia is a psychiatric illness that affects 1% of the population. It is among the top ten causes of disability worldwide and results in enormous economic costs to the Canadian health care system. Various abnormalities in brain structure are frequently observed in patients with schizophrenia, the most common of which are reductions in volume. Importantly, volume deficits are commonly associated with increased symptoms and functional decline, although the mechanism by which they occur is currently unexplained. Glutamate is a brain chemical that can be toxic when present at abnormally high concentrations. Previous literature suggests increased glutamate levels in early and untreated schizophrenia, although levels normalize following effective treatment. Elevated levels of glutamate might cause the aforementioned brain volume losses. Our study aims to explore if glutamate levels are linked with brain loss in a region referred to as the striatum, which is highly involved in schizophrenia. We will investigate this relationship in a never-treated sample of patients who are early in their illness and in treated patients who have had schizophrenia for a significant duration of time. We hypothesize that the former group will have high glutamate levels associated with local volume losses, while no such relationship will exist in the latter group. Glutamate levels and brain volume will be measured using non-invasive magnetic resonance imaging techniques, which have been previously used to show anomalies in both glutamate and brain volume in patients with schizophrenia. Our results will be highly impactful for schizophrenia researchers by leading to an improved understanding of the illness. Additionally, this study will benefit the Canadian health care system, as well as Canadian patients and families affected by schizophrenia, by contributing to the development of new diagnostic and therapeutic strategies, ultimately improving the management and outcomes of the illness.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Plitman, Eric
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~